We are live on
!
Find out more
LC
Lindbrook Capital Portfolio holdings
AUM
$1.08B
1-Year Est. Return
10.14%
This Fund
S&P 500
This Quarter
Est. Return
+7.65%
1 Year Est. Return
+10.14%
3 Year Est. Return
+35.77%
5 Year Est. Return
+141.26%
10 Year Est. Return
–
AUM
$939M
AUM Growth
+$86.2M
(+10%)
Cap. Flow
+$29.6M
Cap. Flow
% of AUM
3.15%
Top 10 Holdings %
Top 10 Hldgs %
46.18%
Holding
2,925
New
150
Increased
988
Reduced
857
Closed
215
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard Total International Stock ETF
VXUS
|
+$5.37M |
| 2 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$3.7M |
| 3 |
Vanguard Morningstar Total Stock Market ETF
VTI
|
+$2.54M |
| 4 |
Invesco QQQ Trust
QQQ
|
+$2.12M |
| 5 |
NVIDIA
NVDA
|
+$1.88M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vertex Pharmaceuticals
VRTX
|
+$6.88M |
| 2 |
State Street Consumer Staples Select Sector SPDR ETF
XLP
|
+$4.62M |
| 3 |
Oaktree Specialty Lending
OCSL
|
+$825K |
| 4 |
MGI
MoneyGram International, Inc. New
MGI
|
+$627K |
| 5 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
+$562K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 16.18% |
| 2 | Technology | 15.3% |
| 3 | Healthcare | 6.27% |
| 4 | Consumer Discretionary | 3.61% |
| 5 | Industrials | 3.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1676
Warby Parker
WRBY
$3.27B
| $6.58K | ﹤0.01% |
+563
| New | +$6.41K |
|
1677
QCR Holdings
QCRH
$1.7B
| $6.57K | ﹤0.01% |
+160
| New | +$6.55K |
|
|
AZEK
1678
DELISTED
The AZEK Co
AZEK
| $6.54K | ﹤0.01% |
216
+8
| +4% | +$207 |
|
1679
Agios Pharmaceuticals
AGIO
$1.93B
| $6.54K | ﹤0.01% |
231
+136
| +143% | +$3.38K |
|
1680
Aldeyra Therapeutics
ALDX
$93.5M
| $6.53K | ﹤0.01% |
778
+417
| +116% | +$4.11K |
|
|
CIVI
1681
DELISTED
Civitas Resources
CIVI
| $6.52K | ﹤0.01% |
94
| – | – |
|
1682
AMC Global Media
AMCX
$489M
| $6.51K | ﹤0.01% |
545
+498
| +1,060% | +$7.18K |
|
1683
Embecta
EMBC
$262M
| $6.48K | ﹤0.01% |
300
+106
| +55% | +$2.89K |
|
1684
GoodRx Holdings
GDRX
$1.26B
| $6.48K | ﹤0.01% |
1,174
+200
| +21% | +$1.08K |
|
|
MESO
1685
Mesoblast
MESO
$2.07B
| $6.48K | ﹤0.01% |
829
-401
| -33% | -$2.87K |
|
1686
A.O. Smith
AOS
$8.7B
| $6.48K | ﹤0.01% |
89
-21
| -19% | -$1.44K |
|
1687
Pembina Pipeline
PBA
$27.6B
| $6.48K | ﹤0.01% |
206
-14,510
| -99% | -$463K |
|
1688
Coherent
COHR
$74.2B
| $6.47K | ﹤0.01% |
127
-36
| -22% | -$1.34K |
|
|
TGI
1689
DELISTED
Triumph Group
TGI
| $6.45K | ﹤0.01% |
521
-100
| -16% | -$1.14K |
|
1690
Crane Co
CR
$12.7B
| $6.42K | ﹤0.01% |
+72
| New | +$5.56K |
|
1691
Carlisle Companies
CSL
$15.4B
| $6.41K | ﹤0.01% |
25
+12
| +92% | +$2.66K |
|
1692
Mohawk Industries
MHK
$9.22B
| $6.4K | ﹤0.01% |
62
+4
| +7% | +$392 |
|
1693
Amplify Cybersecurity ETF
HACK
$2.91B
| $6.32K | ﹤0.01% |
125
| – | – |
|
1694
Northern Oil and Gas
NOG
$2.35B
| $6.32K | ﹤0.01% |
184
| – | – |
|
1695
ANI Pharmaceuticals
ANIP
$1.78B
| $6.3K | ﹤0.01% |
117
| – | – |
|
1696
National Bank Holdings
NBHC
$1.9B
| $6.27K | ﹤0.01% |
216
| – | – |
|
1697
Option Care Health
OPCH
$3.56B
| $6.27K | ﹤0.01% |
193
-96
| -33% | -$2.89K |
|
1698
Monarch Casino & Resort
MCRI
$2.23B
| $6.27K | ﹤0.01% |
89
| – | – |
|
1699
KraneShares Electric Vehicles and Future Mobility Index ETF
KARS
$80.2M
| $6.24K | ﹤0.01% |
200
| – | – |
|
1700
Noble Corp
NE
$6.51B
| $6.2K | ﹤0.01% |
150
+85
| +131% | +$3.27K |
|
Similar funds
SBIA
CHP
MW
TAM
SIA
CIG
CCM
WCF
Lindbrook Capital's Q2 2023 Portfolio in Review
As of Q2 2023, Lindbrook Capital held 2,925 positions worth $939M, up 10% from $853M the previous quarter. Its ten largest holdings account for 46% of the portfolio.
Lindbrook Capital deployed $29.6M of net new capital in Q2 2023, opening 150 new positions and adding to 988 existing holdings. Its largest new stake was UPAR Ultra Risk Parity ETF: 21,000 shares worth $291K.
By sector, the portfolio is most concentrated in Financials at 16% of assets, down from 17% a quarter earlier, followed by Technology and Healthcare.
On the sell side, the largest reduction was Vertex Pharmaceuticals, an estimated $6.88M trimmed.
- Lindbrook Capital's largest Q2 2023 buy was UPAR Ultra Risk Parity ETF: 21,000 shares worth $291K.
- Lindbrook Capital added most to Vanguard Total International Stock ETF in Q2 2023, an estimated $5.37M increase.
- Lindbrook Capital's biggest Q2 2023 reduction was Vertex Pharmaceuticals, cutting an estimated $6.88M.
- Lindbrook Capital fully exited MoneyGram International, Inc. New in Q2 2023, selling an estimated $627K.
- Lindbrook Capital's ten largest holdings make up 46% of its $939M portfolio in Q2 2023.
- Lindbrook Capital opened 150 new positions and closed 215 in Q2 2023.
- Lindbrook Capital's portfolio value rose 10% quarter-over-quarter to $939M.
Based on Lindbrook Capital's 13F filing for Q2 2023, filed 31 Jul 2023.